Header Logo

Connection

CHARLOTTE C SUN to Aged

Back to Details
This is a "connection" page, showing publications CHARLOTTE C SUN has written about Aged.
CHARLOTTE C SUN
Connection Strength
0.599
Aged
  1. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol. 2019 02; 152(2):328-333.
    View in: PubMed
    Score: 0.026
  2. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017 Apr 01; 35(10):1103-1111.
    View in: PubMed
    Score: 0.023
  3. Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):500-5.
    View in: PubMed
    Score: 0.021
  4. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol. 2015 Aug 20; 33(24):2675-82.
    View in: PubMed
    Score: 0.021
  5. Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
    View in: PubMed
    Score: 0.019
  6. Lifestyle modification in cervical cancer survivors: an ongoing need. Int J Gynecol Cancer. 2014 Mar; 24(3):570-5.
    View in: PubMed
    Score: 0.019
  7. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6.
    View in: PubMed
    Score: 0.018
  8. Work related stress among gynecologic oncologists. Gynecol Oncol. 2011 Nov; 123(2):365-9.
    View in: PubMed
    Score: 0.016
  9. Religious and spiritual beliefs of gynecologic oncologists may influence medical decision making. Int J Gynecol Cancer. 2011 Apr; 21(3):573-81.
    View in: PubMed
    Score: 0.015
  10. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005 Apr; 13(4):219-27.
    View in: PubMed
    Score: 0.010
  11. Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.
    View in: PubMed
    Score: 0.010
  12. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 06; 185:101-107.
    View in: PubMed
    Score: 0.009
  13. Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer. 2023 05 01; 33(5):749-754.
    View in: PubMed
    Score: 0.009
  14. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer. 2022 09 06; 32(9):1153-1163.
    View in: PubMed
    Score: 0.008
  15. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer. 2022 07 04; 32(7):899-905.
    View in: PubMed
    Score: 0.008
  16. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data. JCO Clin Cancer Inform. 2022 03; 6:e2100187.
    View in: PubMed
    Score: 0.008
  17. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer. 2021 Nov 15; 127(22):4151-4160.
    View in: PubMed
    Score: 0.008
  18. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.007
  19. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658.
    View in: PubMed
    Score: 0.007
  20. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
    View in: PubMed
    Score: 0.007
  21. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
    View in: PubMed
    Score: 0.007
  22. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
    View in: PubMed
    Score: 0.007
  23. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
    View in: PubMed
    Score: 0.007
  24. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
    View in: PubMed
    Score: 0.006
  25. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
    View in: PubMed
    Score: 0.006
  26. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
    View in: PubMed
    Score: 0.006
  27. Gynecologic cancer survivor preferences for long-term surveillance. BMC Cancer. 2018 04 03; 18(1):375.
    View in: PubMed
    Score: 0.006
  28. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
    View in: PubMed
    Score: 0.006
  29. Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
    View in: PubMed
    Score: 0.006
  30. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.006
  31. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017 08; 146(2):399-404.
    View in: PubMed
    Score: 0.006
  32. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
    View in: PubMed
    Score: 0.006
  33. The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. Int J Gynecol Cancer. 2017 05; 27(4):838-846.
    View in: PubMed
    Score: 0.006
  34. Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer. 2017 06; 25(6):1985-1991.
    View in: PubMed
    Score: 0.006
  35. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol. 2017 04; 145(1):37-40.
    View in: PubMed
    Score: 0.006
  36. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
    View in: PubMed
    Score: 0.006
  37. Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY). 2016 08; 41(8):1589-95.
    View in: PubMed
    Score: 0.006
  38. Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. 2016 09; 142(3):525-30.
    View in: PubMed
    Score: 0.006
  39. Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016 Feb; 140(2):295-300.
    View in: PubMed
    Score: 0.005
  40. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer. 2015 Nov 03; 113(9):1254-8.
    View in: PubMed
    Score: 0.005
  41. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.005
  42. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol. 2015 Sep; 138(3):727-30.
    View in: PubMed
    Score: 0.005
  43. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015 Aug; 138(2):388-93.
    View in: PubMed
    Score: 0.005
  44. Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
    View in: PubMed
    Score: 0.005
  45. Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. Gynecol Oncol. 2015 Jan; 136(1):65-70.
    View in: PubMed
    Score: 0.005
  46. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015 Jan; 136(1):25-9.
    View in: PubMed
    Score: 0.005
  47. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
    View in: PubMed
    Score: 0.005
  48. Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010). Eur J Cancer. 2014 Jul; 50(11):1942-50.
    View in: PubMed
    Score: 0.005
  49. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila). 2014 Jul; 7(7):686-97.
    View in: PubMed
    Score: 0.005
  50. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol. 2013 Dec; 231(4):449-56.
    View in: PubMed
    Score: 0.005
  51. Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil. Int J Gynecol Cancer. 2013 Oct; 23(8):1520-7.
    View in: PubMed
    Score: 0.005
  52. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61.
    View in: PubMed
    Score: 0.005
  53. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
    View in: PubMed
    Score: 0.004
  54. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage. 2013 Dec; 46(6):837-45.
    View in: PubMed
    Score: 0.004
  55. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012 Jun; 125(3):661-6.
    View in: PubMed
    Score: 0.004
  56. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
    View in: PubMed
    Score: 0.004
  57. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol. 2012 Apr; 125(1):241-4.
    View in: PubMed
    Score: 0.004
  58. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.004
  59. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol. 2011 Nov; 123(2):333-6.
    View in: PubMed
    Score: 0.004
  60. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
    View in: PubMed
    Score: 0.004
  61. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol. 2011 Jun 01; 121(3):482-6.
    View in: PubMed
    Score: 0.004
  62. Ethics consultation on a gynecologic oncology service: an opportunity for physician education. J Cancer Educ. 2011 Mar; 26(1):183-7.
    View in: PubMed
    Score: 0.004
  63. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011 Aug 15; 117(16):3741-9.
    View in: PubMed
    Score: 0.004
  64. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes. Int J Gynecol Cancer. 2011 Jan; 21(1):123-7.
    View in: PubMed
    Score: 0.004
  65. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.004
  66. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010 Dec; 116(6):1358-1365.
    View in: PubMed
    Score: 0.004
  67. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.
    View in: PubMed
    Score: 0.004
  68. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.004
  69. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.
    View in: PubMed
    Score: 0.004
  70. Survival after intestinal perforation: can it be predicted? Gynecol Oncol. 2009 Dec; 115(3):349-53.
    View in: PubMed
    Score: 0.003
  71. Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol. 2009 Jul; 114(1):93-99.
    View in: PubMed
    Score: 0.003
  72. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 01; 115(9):1867-74.
    View in: PubMed
    Score: 0.003
  73. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.003
  74. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
    View in: PubMed
    Score: 0.003
  75. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502.
    View in: PubMed
    Score: 0.003
  76. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008 May; 206(5):833-46; discussion 846-8.
    View in: PubMed
    Score: 0.003
  77. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract. 2008 Mar; 14(1):31-6.
    View in: PubMed
    Score: 0.003
  78. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar; 108(3):510-4.
    View in: PubMed
    Score: 0.003
  79. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008 Jul-Aug; 18(4):660-9.
    View in: PubMed
    Score: 0.003
  80. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol. 2007 Dec; 107(3):458-63.
    View in: PubMed
    Score: 0.003
  81. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007 Jul; 246(1):52-60.
    View in: PubMed
    Score: 0.003
  82. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol. 2007 Jul; 110(1):96-102.
    View in: PubMed
    Score: 0.003
  83. The learning curve in pancreatic surgery. Surgery. 2007 May; 141(5):694-701.
    View in: PubMed
    Score: 0.003
  84. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun; 105(3):625-9.
    View in: PubMed
    Score: 0.003
  85. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May; 105(2):404-8.
    View in: PubMed
    Score: 0.003
  86. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20.
    View in: PubMed
    Score: 0.003
  87. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.003
  88. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006 Jun 01; 106(11):2452-8.
    View in: PubMed
    Score: 0.003
  89. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006 Sep; 102(3):468-74.
    View in: PubMed
    Score: 0.003
  90. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
    View in: PubMed
    Score: 0.003
  91. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74.
    View in: PubMed
    Score: 0.003
  92. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004 Oct; 95(1):133-8.
    View in: PubMed
    Score: 0.002
  93. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 01; 22(15):3126-32.
    View in: PubMed
    Score: 0.002
  94. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol. 2004 Aug; 104(2):255-60.
    View in: PubMed
    Score: 0.002
  95. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004 Aug; 94(2):456-62.
    View in: PubMed
    Score: 0.002
  96. Evaluation of patient chemotherapy education in a gynecology oncology center. Support Care Cancer. 2004 Aug; 12(8):577-83.
    View in: PubMed
    Score: 0.002
  97. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol. 2004 Feb; 92(2):586-91.
    View in: PubMed
    Score: 0.002
  98. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol. 2000 Aug; 78(2):235-41.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.